Physician profile
Joel Chandy
NPI 1073992152
$3,052.26
in general payments reported to CMS, 2019-2025
24 companies · $887 in 2025
The $887 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2021: $222 · 2022: $317 · 2023: $819 · 2024: $688 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,393.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,132.05 | 2021-2025 | Linzess, Viberzi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $304.93 | 2024-2025 | Xifaxan |
| Ardelyx, INC. | $209.10 | 2022-2025 | Ibsrela |
| Pfizer INC. | $181.79 | 2019-2025 | |
| Davol INC. | $159.95 | 2023 | Phasix Mesh |
| Celgene Corporation | $123.27 | 2022-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $117.53 | 2021 | |
| Genzyme Corporation | $89.84 | 2022-2024 | |
| Intercept Pharmaceuticals, INC. | $84.24 | 2023-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $80.61 | 2021-2024 | Eohilia |
| Daiichi Sankyo INC. | $73.36 | 2023-2024 | Injectafer |
| Ironwood Pharmaceuticals, INC | $68.35 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $55.89 | 2024-2025 | Voquezna |
| Endogastric Solutions, INC | $54.67 | 2024 | Esophyx |
| Ferring Pharmaceuticals INC. | $53.44 | 2021-2023 | Cimzia |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $50.11 | 2023-2025 | Dupixent |
| Madrigal Pharmaceuticals | $48.21 | 2024 | Resmetirom |
| Lilly USA, LLC | $38.31 | 2025 | Omvoh |
| Redhill Biopharma INC. | $34.43 | 2021-2023 | |
| Qol Medical, LLC | $24.49 | 2024 | Sucraid |
| Ipsen Biopharmaceuticals, INC | $23.30 | 2025 | Iqirvo |
| Sandoz INC. | $15.64 | 2023 | Hyrimoz |
| Evoke Pharma, INC. | $15.10 | 2025 | |
| Janssen Biotech, INC. | $13.65 | 2023 | Stelara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Chandy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.